Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Memphasys Ltd ( (AU:MEM) ) has issued an announcement.
Memphasys Limited has issued 26 million fully paid ordinary shares at a deemed issue price of $0.003 per share as consideration for corporate advisory and other services, following shareholder approvals granted at its 20 November 2025 Annual General Meeting. The company has confirmed that the shares were issued without a prospectus under the Corporations Act’s secondary trading provisions, that it remains compliant with its continuous disclosure and reporting obligations, and that there is no excluded information, thereby facilitating on-market secondary trading of the new securities and signalling routine capital management to support its commercial activities.
The most recent analyst rating on (AU:MEM) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Memphasys Ltd stock, see the AU:MEM Stock Forecast page.
More about Memphasys Ltd
Memphasys Limited (ASX: MEM) is an Australian-based reproductive biotechnology company commercialising the Felix™ System, a patented bioseparation technology used to isolate the most viable sperm cells for human assisted reproduction. The system combines electrophoresis and size-exclusion membranes to provide a fast, gentle and standardised sperm selection process that replaces traditional centrifugation, aiming to enhance sperm quality, reduce laboratory time and become a new global standard in sperm preparation for IVF through both direct and distribution-led sales channels.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$20.92M
For an in-depth examination of MEM stock, go to TipRanks’ Overview page.